Research ArticleArticle
Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis
Vibeke Strand, Grace C. Wright, Martin J. Bergman, Jeyanesh Tambiah and Peter C. Taylor
The Journal of Rheumatology August 2015, jrheum.140976; DOI: https://doi.org/10.3899/jrheum.140976
Vibeke Strand
From Division of Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA; New York University Langone Medical Center, New York, NY; Drexel University College of Medicine, Philadelphia, PA; UCB Pharma, Smyrna, GA, USA; Kennedy Institute of Rheumatology, Oxford, UK. Funded by UCB Pharma. V. Strand, G.C. Wright, and M.J. Bergman are consultants for UCB Pharma; J. Tambiah is an employee and shareholder of UCB Pharma; Peter Taylor is a consultant for, and has received research grants from, UCB Pharma. V. Strand, MD, FACP, FACR, Biopharmaceutical Consultant; Adjunct Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.C. Wright, MD, New York University Langone Medical Center; M.J. Bergman, MD, Drexel University College of Medicine; J. Tambiah, MD, UCB Pharma; P.C. Taylor, MD, Kennedy Institute of Rheumatology. Address correspondence to Dr. Strand, Biopharmaceutical Consultant, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California 94028, USA. E-mail: vstrand@stanford.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 4, 2015.
Grace C. Wright
From Division of Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA; New York University Langone Medical Center, New York, NY; Drexel University College of Medicine, Philadelphia, PA; UCB Pharma, Smyrna, GA, USA; Kennedy Institute of Rheumatology, Oxford, UK. Funded by UCB Pharma. V. Strand, G.C. Wright, and M.J. Bergman are consultants for UCB Pharma; J. Tambiah is an employee and shareholder of UCB Pharma; Peter Taylor is a consultant for, and has received research grants from, UCB Pharma. V. Strand, MD, FACP, FACR, Biopharmaceutical Consultant; Adjunct Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.C. Wright, MD, New York University Langone Medical Center; M.J. Bergman, MD, Drexel University College of Medicine; J. Tambiah, MD, UCB Pharma; P.C. Taylor, MD, Kennedy Institute of Rheumatology. Address correspondence to Dr. Strand, Biopharmaceutical Consultant, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California 94028, USA. E-mail: vstrand@stanford.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 4, 2015.
Martin J. Bergman
From Division of Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA; New York University Langone Medical Center, New York, NY; Drexel University College of Medicine, Philadelphia, PA; UCB Pharma, Smyrna, GA, USA; Kennedy Institute of Rheumatology, Oxford, UK. Funded by UCB Pharma. V. Strand, G.C. Wright, and M.J. Bergman are consultants for UCB Pharma; J. Tambiah is an employee and shareholder of UCB Pharma; Peter Taylor is a consultant for, and has received research grants from, UCB Pharma. V. Strand, MD, FACP, FACR, Biopharmaceutical Consultant; Adjunct Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.C. Wright, MD, New York University Langone Medical Center; M.J. Bergman, MD, Drexel University College of Medicine; J. Tambiah, MD, UCB Pharma; P.C. Taylor, MD, Kennedy Institute of Rheumatology. Address correspondence to Dr. Strand, Biopharmaceutical Consultant, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California 94028, USA. E-mail: vstrand@stanford.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 4, 2015.
Jeyanesh Tambiah
From Division of Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA; New York University Langone Medical Center, New York, NY; Drexel University College of Medicine, Philadelphia, PA; UCB Pharma, Smyrna, GA, USA; Kennedy Institute of Rheumatology, Oxford, UK. Funded by UCB Pharma. V. Strand, G.C. Wright, and M.J. Bergman are consultants for UCB Pharma; J. Tambiah is an employee and shareholder of UCB Pharma; Peter Taylor is a consultant for, and has received research grants from, UCB Pharma. V. Strand, MD, FACP, FACR, Biopharmaceutical Consultant; Adjunct Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.C. Wright, MD, New York University Langone Medical Center; M.J. Bergman, MD, Drexel University College of Medicine; J. Tambiah, MD, UCB Pharma; P.C. Taylor, MD, Kennedy Institute of Rheumatology. Address correspondence to Dr. Strand, Biopharmaceutical Consultant, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California 94028, USA. E-mail: vstrand@stanford.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 4, 2015.
Peter C. Taylor
From Division of Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA; New York University Langone Medical Center, New York, NY; Drexel University College of Medicine, Philadelphia, PA; UCB Pharma, Smyrna, GA, USA; Kennedy Institute of Rheumatology, Oxford, UK. Funded by UCB Pharma. V. Strand, G.C. Wright, and M.J. Bergman are consultants for UCB Pharma; J. Tambiah is an employee and shareholder of UCB Pharma; Peter Taylor is a consultant for, and has received research grants from, UCB Pharma. V. Strand, MD, FACP, FACR, Biopharmaceutical Consultant; Adjunct Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.C. Wright, MD, New York University Langone Medical Center; M.J. Bergman, MD, Drexel University College of Medicine; J. Tambiah, MD, UCB Pharma; P.C. Taylor, MD, Kennedy Institute of Rheumatology. Address correspondence to Dr. Strand, Biopharmaceutical Consultant, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California 94028, USA. E-mail: vstrand@stanford.edu. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 4, 2015.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis
Vibeke Strand, Grace C. Wright, Martin J. Bergman, Jeyanesh Tambiah, Peter C. Taylor
The Journal of Rheumatology Aug 2015, jrheum.140976; DOI: 10.3899/jrheum.140976